Hybrigenics, a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia.
Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia